Treprostinil inhibits proliferation and extracellular matrix deposition by fibroblasts through cAMP activation
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Idiopathic pulmonary fibrosis (IPF) is characterized by peripheral lung fibrosis and increased interstitial extracellular matrix (ECM) deposition. In IPF, tumor growth factor (TGF)-β1 which is the major stimulus of ECM deposition, and platelet derived growth factor (PDGF)-BB is a potent stimulus of fibrosis. Thus, the effect of Treprostinil on TGF-ß1 and PDGF-induced fibroblast proliferation and ECM deposition was investigated. Human peripheral lung fibroblasts of seven IPF patients and five lung donors were stimulated by PDGF, or TGF-β1, or the combination. Cells were pre-incubated (30 min) with either Treprostinil, forskolin, di-deoxyadenosine (DDA), or vehicle. Treprostinil time dependently activated cAMP thereby preventing PDGF-BB induced proliferation and TGF-β1 secretion. Cell counts indicated proliferation; α-smooth muscle actin (α-SMA) indicted differentiation, and collagen type-1 or fibronectin deposition remodeling. Myo-fibroblast indicating α-SMA expression was significantly reduced and its formation was altered by Treprostinil. Collagen type-I and fibronectin deposition were also reduced by Treprostinil. The effect of Treprostinil on collagen type-I deposition was cAMP sensitive as it was counteracted by DDA, while the effect on fibronectin was not cAMP mediated. Treprostinil antagonized the pro-fibrotic effects of both PDGF-BB and TGF-β1 in primary human lung fibroblasts. The data presented propose a therapeutic relevant anti-fibrotic effect of Treprostinil in IPF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Bersiposocin (DWN12088) is a PARS1 inhibitor, which leads to downregulation of collagen synthesis, and thus is a potential therapeutic target in pulmonary fibrosis where excessive collagen deposition is a major pathological feature [124].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [124]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Prostanoid Receptors: Structures, Properties, and Functions
Narumiya, S., Sugimoto, Y., & Ushikubi, F. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1193 · Cited by 2,412
TGF-β signaling and the fibrotic response
Leask, A., & Abraham, D. J. (2004) · The FASEB Journal · doi:10.1096/fj.03-1273rev · Cited by 2,319
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Gross, T. J., & Hunninghake, G. W. (2001) · New England Journal of Medicine · doi:10.1056/nejmra003200 · Cited by 962
Bleomycin in the setting of lung fibrosis induction: From biological mechanisms to counteractions
Della Latta, V., Cecchettini, A., Del Ry, S., & Morales, M. A. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.04.012 · Cited by 514
Zhou, B., Liu, Y., Kahn, M., Ann, D. K., Han, A., Wang, H., Nguyen, C., Flodby, P., Zhong, Q., Krishnaveni, M. S., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.276311 · Cited by 261
Hostettler, K. E., Zhong, J., Papakonstantinou, E., Karakiulakis, G., Tamm, M., Seidel, P., Sun, Q., Mandal, J., Lardinois, D., Lambers, C., et al. (2014) · Respiratory Research · doi:10.1186/s12931-014-0157-3 · Cited by 258
Self-citation
Cited by
Nathan, S. D., Waxman, A., Rajagopal, S., Case, A., Johri, S., DuBrock, H., De La Zerda, D. J., Sahay, S., King, C., Melendres-Groves, L., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00165-x · Cited by 152
The vascular perspective on acute and chronic lung disease
Borek, I., Birnhuber, A., Voelkel, N. F., Marsh, L. M., & Kwapiszewska, G. (2023) · Journal of Clinical Investigation · doi:10.1172/jci170502 · Cited by 103
“GK is a speaker for the Austrian Science Fund (FWF) DOC from direct improvements in the vascular compartment that occur as a consequence of inhibition of parenchymal fibroblast proliferation or from modulation of the local inflammatory milleu (174, 175).”
Group 3 Pulmonary Hypertension: From Bench to Bedside
Singh, N., Dorfmüller, P., Shlobin, O. A., & Ventetuolo, C. E. (2022) · Circulation Research · doi:10.1161/circresaha.121.319970 · Cited by 98
Nathan, S. D., Behr, J., Cottin, V., Lancaster, L., Smith, P., Deng, C., Pearce, N., Bell, H., Peterson, L., & Flaherty, K. R. (2022) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2022-001310 · Cited by 73
Recent advances in the management of pulmonary hypertension with interstitial lung disease
Waxman, A. B., Elia, D., Adir, Y., Humbert, M. J. C., & Harari, S. A. (2022) · European Respiratory Review · doi:10.1183/16000617.0220-2021 · Cited by 71
Metadata
- Authors
- Lambers, C., Roth, M., Jaksch, P., Muraközy, G., Tamm, M., Klepetko, W., Ghanim, B., & Zhao, F.
- Affiliations
- Medical University of Vienna (AT)
- University of Basel (CH)
- Corresponding author
- Lambers, Christopher
- Venue
- Scientific Reports
- Published
- 2018-01-18
- Volume
- 8
- Issue
- 1
- Pages
- 1087-1087
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC5773699
- OpenAlex
- W2783225214
- Cited by
- 61
- References
- 43
- Citations by year
- 2026: 10 · 2025: 9 · 2024: 7 · 2023: 12 · 2022: 7 · 2021: 7 · 2020: 6 · 2019: 2 · 2018: 1
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- treprostinil, idiopathic pulmonary fibrosis, lung fibroblasts, fibroblast proliferation, extracellular matrix deposition, cAMP signaling, TGF-β1, PDGF-BB, myofibroblast differentiation, alpha-smooth muscle actin, type I collagen, fibronectin, antifibrotic therapy
- MeSH terms
- Cyclic AMP, Cells, Cultured, Extracellular Matrix, Fibroblasts, Humans, Epoprostenol, Biomarkers, Cell Proliferation, Transforming Growth Factor beta1, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treprostinil inhibits proliferation and extracellular matrix deposition by fibroblasts through cAMP activation. https://app.cochat.ai/papers/10.1038/s41598-018-19294-1
- The paper
- Lambers, C., Roth, M., Jaksch, P., Muraközy, G., Tamm, M., Klepetko, W., Ghanim, B., & Zhao, F. (2018). Treprostinil inhibits proliferation and extracellular matrix deposition by fibroblasts through cAMP activation. Scientific Reports. https://doi.org/10.1038/s41598-018-19294-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.